AZRX - AzurRx BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8499
+0.0151 (+1.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8348
Open0.8361
Bid0.8300 x 1000
Ask0.8499 x 3000
Day's Range0.8292 - 0.8700
52 Week Range0.3710 - 1.9380
Volume55,980
Avg. Volume291,972
Market Cap23.97M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • GlobeNewswire

    AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product

    Under the terms of the agreement, Creapharm will package, label, provide qualified person (QP) release and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy clinical trials for the treatment of EPI in patients with Cystic Fibrosis (CF). MS1819 clinical trial drug supply will be sent directly to clinical sites in the U.S. and in Europe, including, Poland, Hungary, Spain and Turkey from Creapharm’s U.S. and European depots, respectively.

  • GlobeNewswire

    AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)

    This marks the third CIR payment AzurRx SAS has received in 2020. Since March including the 2019 CIR, the Company has received approximately $2.52 million in non-dilutive funding in research tax credits from the French government.

  • GlobeNewswire

    AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

    IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the.

  • GlobeNewswire

    AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites

    On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsulesTrial.

  • GlobeNewswire

    AzurRx BioPharma Issues Letter to Shareholders

    AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer. When I last wrote to you six months ago (on October 22, 2019), as the newly appointed President and CEO of AzurRx, I spoke about my strong belief in the potential of MS1819, our focus on building shareholder value and in raising sufficient capital to achieve our milestones. Despite COVID-19, we currently anticipate only minor delays in initiating and completing our dose-escalating Phase 2 OPTION 2 monotherapy clinical trial, using 2.2g and 4.4g doses of MS1819 in enteric capsules in the U.S. and Poland.

  • GlobeNewswire

    Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX)

    NEW YORK, April 20, 2020 -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on AzurRx BioPharma, Inc.  (NasdaqCM: AZRX).

  • GlobeNewswire

    AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product

    Under the terms of the agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibrosis (CF). As preparation for the cGMP batch, the drug product manufacturing process was transferred to Delpharm and they have successfully produced a non-GMP batch.

  • ACCESSWIRE

    AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020

    BROOKLYN, NY / ACCESSWIRE / April 15, 2020 / AzurRx BioPharma, Inc. (NASDAQ:AZRX), is a clinical stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of ...

  • GlobeNewswire

    AzurRx Appoints Gregory Oakes to its Board of Directors

    “Greg is a strong and welcomed addition to our board,” said James Sapirstein, CEO of AzurRx BioPharma. "I am excited to join the AzurRx Board with its compelling potential synthetic alternative to PERT therapy,” said Mr. Oakes. “I look forward to helping the Company realize the full commercial potential of the MS1819 program."

  • GlobeNewswire

    AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)

    In March 2020, the Company announced it had received $1.13 million for its 2018 CIR for an aggregate total of $1.77 million in non-dilutive funding received in 2020. In addition, the Company anticipates it will receive the 2019 CIR payment by the end of 2020. The CIR has been used to fund AzurRx’s ongoing MS1819 clinical trials, including its Phase 2 Combination therapy study in Cystic Fibrosis.

  • ACCESSWIRE

    AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th

    NEW YORK, NY / ACCESSWIRE / March 18, 2020 / AzurRx BioPharma (NASDAQ:AZRX) will be presenting at this year's Spring Investor Summit on March 25 th -26 th . During the current climate of concern, The Spring ...

  • GlobeNewswire

    AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)

    The French R&D tax credit initiative (“Crédit d’Impôt Recherche”, or CIR) gives eligible research-based French companies, which are subject to corporate tax in France, the ability to claim tax relief of up to 30% on costs incurred in R&D activities. “The 30% tax relief on R&D activities provides a significant non-dilutive funding source for our on-going research and clinical trial activities in France and Europe through our AzurRx SAS subsidiary,” said James Sapirstein, the CEO of AzurRx. The Research Tax Credit (CIR) is a tax incentive provided by the French Government to encourage the growth of businesses' competitiveness by favoring research and development (R&D) and innovative activities.

  • GlobeNewswire

    AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference

    The presentation, entitled: “Results from a Phase 2, Open-Label, Multicenter, 2x2 Cross-over Trial to Assess the Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,” will be delivered by Dr. Michael Konstan, Vice Dean for Translational Research and Professor of Pediatrics at Case Western Reserve University in Cleveland, Ohio. Dr. Konstan will discuss the data from the Company’s Phase II study of MS1819 in patients with cystic fibrosis, which demonstrated safety, a coefficient of fat absorption (CFA) which was similar to the value at the same dose in a prior study in chronic pancreatitis, and positive unexpected findings on the coefficient of nitrogen absorption (CNA).

  • GlobeNewswire

    AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

    Alexander Capital, LP acted as sole placement agent in the Offering. Net proceeds from the Offering will be used to eliminate short- and long-term indebtedness, and for general working capital purposes, including product development. The Offering consisted of Senior Convertible Promissory Notes (the “Notes”) and warrants (the “Warrants”) to purchase shares of the Company’s common stock (the “Common Stock”).

  • GlobeNewswire

    AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

    Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD,.

  • GlobeNewswire

    AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

    BROOKLYN, N.Y., Jan. 06, 2020 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.

  • GlobeNewswire

    AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

    NEW YORK, Jan. 03, 2020 -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies.

  • GlobeNewswire

    AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

    Under the purchase agreement, AzurRx will have the right to sell up to $15 million of its stock to Lincoln Park over a 30-month period, upon satisfaction of the conditions in the purchase agreement, including after a registration statement registering the resale of shares to be sold to Lincoln Park under the purchase agreement is declared effective by the Securities and Exchange Commission (SEC). AzurRx, from time to time over a 30 month period, will have the right, at its sole discretion, to sell up to $15 million of its stock to Lincoln Park.

  • GlobeNewswire

    AzurRx BioPharma CEO Issues Letter to Shareholders

    AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following letter to its shareholders and the investment community from its newly appointed CEO, James Sapirstein. It is with great pleasure that I am writing to you as the new President and Chief Executive Officer of AzurRx BioPharma, Inc. By way of background, I have over 35 years of pharmaceutical industry experience spanning areas such as drug development and commercialization.

  • GlobeNewswire

    AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Cystic Fibrosis Foundation (CFF) Data Safety Monitoring Board (DSMB) has completed  its review of the Company’s final results of the Phase 2 OPTION trial and has found no safety concerns for MS1819-SD. Additionally, the group supports the Company’s plan to proceed to a higher 4-gram dose of MS1819-SD in its next planned Phase 2 clinical trial.

  • GlobeNewswire

    AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has dosed the first patients in its Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF) who suffer from severe exocrine pancreatic insufficiency (EPI).

  • GlobeNewswire

    AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that James Sapirstein has been appointed to serve as the Company’s President and Chief Executive Officer following the resignation of Thijs Spoor from the same positions. Mr. Sapirstein, who most recently served as chief executive officer and board member for ContraVir Pharmaceuticals, Inc. (now known as Hepion Pharmaceuticals, Inc. (NASADQ:HEPA)), has nearly 36 years of pharmaceutical industry experience spanning areas such as drug development and commercialization.

  • GlobeNewswire

    AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

    Results showed that the primary efficacy endpoint of coefficient of fat absorption (CFA) was comparable to the CFA in a prior phase 2 study in patients with chronic pancreatitis, while using the same dose of MS1819.  The dose used in both studies was 2 gram/day, which was selected in agreement with FDA as a bridging dose. Although the study was not powered for statistical significance, the data also demonstrated meaningful efficacy results, with approximately 50% of the patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies (PERT).

  • GlobeNewswire

    AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, reported financial results for the three and six months ended June 30, 2019 and highlighted recent corporate progress. Announced that the first patients were dosed in an open-label, cross-over Phase II OPTION Study with MS1819-SD for exocrine pancreatic insufficiency (“EPI”) in cystic fibrosis (“CF”) in February 2019 and that the study enrollment target was met in May 2019. The Company continues to expect results from the study in September 2019.

  • ACCESSWIRE

    AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock

    BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. The Company also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock, at the public offering price, less underwriting discounts and commissions.